Lead program
Neurodegeneration
Conformer-selective Aβ binder — Alzheimer’s disease
- Discovery
- Lead optimisation
- Preclinical
- IND-enabling
- Target
- The soluble, protofibrillar form of amyloid-β — the species most associated with toxicity, recapitulating the conformational-selectivity logic validated clinically by protofibril-targeting antibodies.
- Approach
- A compact, de novo protein binder designed to recognise the protofibril’s exposed N-terminal epitope while avoiding monomer, mature fibril, and vascular deposits — an effector-format-independent design intended to maximise selectivity.
- Stage
- Computational design & in-silico validation.